Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Implementation Intervention.
- Who it may be relevant to
- Registry conditions: Alcohol Use Disorder, Alcohol-associated Liver Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Feasibility and Acceptability of a Novel Implementation Intervention to Promote Alcohol Use Disorder Treatment in Hepatology Clinics
Overview
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.
Interventions
- Behavioral Implementation Intervention
A multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested.
Primary outcome measures
- Feasibility [Time frame: 12 months]
Secondary outcome measures (1)
- Acceptability [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.
Exclusion criteria
- Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Health services research
Study locations
United States · 1 center
- Yale School of Medicine/Yale-New Haven Health — New Haven
Identifiers
NCT: NCT07525258 · 2000038799 · 1K23AA031334-01